Next Article in Journal
Evaluating the Impact of Telehealth-Based, Diabetes Medication Training for Community Health Workers on Glycemic Control
Next Article in Special Issue
RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
Previous Article in Journal
Application of Noninvasive Vagal Nerve Stimulation to Stress-Related Psychiatric Disorders
Review

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice

Division of Hematology, University of Siena, 53100 Siena, Italy
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2020, 10(3), 120; https://doi.org/10.3390/jpm10030120
Received: 19 July 2020 / Revised: 3 September 2020 / Accepted: 8 September 2020 / Published: 10 September 2020
(This article belongs to the Special Issue Personalized Targeted Therapy for Multiple Myeloma)
Novel drugs have revolutionized multiple myeloma therapy in the last 20 years, with median survival that has doubled to up to 8–10 years. The introduction of therapeutic strategies, such as consolidation and maintenance after autologous stem cell transplants, has also ameliorated clinical results. The goal of modern therapies is becoming not only complete remission, but also the deepest possible remission. In this context, the evaluation of minimal residual disease by techniques such as next-generation sequencing (NGS) and next-generation flow (NGF) is becoming part of all new clinical trials that test drug efficacy. This review focuses on minimal residual disease approaches in clinical trials, with particular attention to real-world practices. View Full-Text
Keywords: multiple myeloma; minimal residual disease; next-generation flow cytometry; next-generation sequencing; complete remission multiple myeloma; minimal residual disease; next-generation flow cytometry; next-generation sequencing; complete remission
Show Figures

Graphical abstract

MDPI and ACS Style

Gozzetti, A.; Raspadori, D.; Bacchiarri, F.; Sicuranza, A.; Pacelli, P.; Ferrigno, I.; Tocci, D.; Bocchia, M. Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice. J. Pers. Med. 2020, 10, 120. https://doi.org/10.3390/jpm10030120

AMA Style

Gozzetti A, Raspadori D, Bacchiarri F, Sicuranza A, Pacelli P, Ferrigno I, Tocci D, Bocchia M. Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice. Journal of Personalized Medicine. 2020; 10(3):120. https://doi.org/10.3390/jpm10030120

Chicago/Turabian Style

Gozzetti, Alessandro, Donatella Raspadori, Francesca Bacchiarri, Anna Sicuranza, Paola Pacelli, Ilaria Ferrigno, Dania Tocci, and Monica Bocchia. 2020. "Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice" Journal of Personalized Medicine 10, no. 3: 120. https://doi.org/10.3390/jpm10030120

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop